Recherche
-
Effectiveness and safety of standard and reduced doses of dabigatran versus rivaroxaban in non-valvular atrial fibrillation: A cohort study in the snds french nationwide claims database
(Value Health. vol. 21, pp. S7-S7, 2018-10)Article de revue -
Benefit-risk profile of dabigatran compared with vitamin-K antagonists in elderly patients with non-valvular atrial fibrillation: results from a cohort study in the French nationwide claims database
(European Heart Journal. vol. 39, pp. 822-822, 2018-08)Article de revue -
Pharmacoepidemiology of non-steroidal anti-inflammatory drugs
(Therapie. vol. 74, n° 2, pp. 271-277, 2019-04)Article de revue -
Global epidemiology of hip fractures: a study protocol using a common analytical platform among multiple countries
(BMJ Open. vol. 11, n° 7, pp. e047258, 2021-07-28)Article de revueLibre accès -
Drug exposure and risk of Acute Liver Failure leading to registration for liver Transplantation (ALFT): Results of the SALT III study in adults in France
(J. Hepatol.. vol. 68, pp. S587-S588, 2018-04)Article de revue -
Comparative Effectiveness and Safety of Standard or Reduced Dose Dabigatran vs. Rivaroxaban in Nonvalvular Atrial Fibrillation
(Clinical Pharmacology and Therapeutics. vol. 105, n° 6, pp. 1439-1455, 2019)Article de revue -
Correction to: Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS
(American Journal of Cardiovascular Drugs, 2021-12-21)Article de revue -
NSAIDs and COVID-19: A Systematic Review and Meta-analysis
(Drug Safety. vol. 44, n° 9, pp. 929-938, 2021-09)Article de revue -
Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins for the prevention of venous thromboembolism after total hip or knee replacement: A nationwide database cohort study
(Pharmacological Research. vol. 141, pp. 201-207, 2019)Article de revue -
Bismuth Concentrations in Patients Treated in Real-Life Practice with a Bismuth Subcitrate-Metronidazole-Tetracycline Preparation: The SAPHARY Study
(Drug safety. vol. 42, n° 8, pp. 993-1003, 2019-08)Article de revue